These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32041745)

  • 1. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Kamal F; Khan MA; Ahmed A; Nair S
    Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Teng YX; Li MJ; Xiang BD; Zhong JH
    Gut; 2020 Oct; 69(10):1900-1902. PubMed ID: 31843789
    [No Abstract]   [Full Text] [Related]  

  • 3. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
    Lee SW; Choi J; Kim SU; Lim YS
    Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
    Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
    JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
    Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
    Na JE; Sinn DH; Lee JH; Jang HJ; Baek SY; Kim KA; Kang WS; Gwak GY; Paik YH; Kim YJ; Choi MS; Yoon JH; Lee JH; Koh KC; Paik SW
    J Viral Hepat; 2021 Oct; 28(10):1392-1399. PubMed ID: 34251707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum KJ; Sonneveld MJ
    Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149
    [No Abstract]   [Full Text] [Related]  

  • 8. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
    Yuan J; Peng Y; Hao FB; Wang YQ; Wang CR; Zhong GC
    Aging (Albany NY); 2021 Feb; 13(5):7147-7165. PubMed ID: 33658397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
    Gu L; Yao Q; Shen Z; He Y; Ng DM; Yang T; Chen B; Chen P; Mao F; Yu Q
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1467-1476. PubMed ID: 32180249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
    Huang R; Liu J; Wang J; Wu C
    Aliment Pharmacol Ther; 2021 May; 53(9):1040-1041. PubMed ID: 33831236
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
    Chiu SY; Chang KC; Hu TH; Chien RN
    Aliment Pharmacol Ther; 2021 May; 53(9):1042-1043. PubMed ID: 33831240
    [No Abstract]   [Full Text] [Related]  

  • 14. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
    Wang JG; Chen R; Wang LC
    Aliment Pharmacol Ther; 2021 May; 53(9):1048-1049. PubMed ID: 33831238
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
    Pol S; Lusivika Nzinga C; Carrat F
    Aliment Pharmacol Ther; 2021 May; 53(9):1050. PubMed ID: 33831235
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
    Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
    J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can tertiary prevention of hepatocellular carcinoma be achieved by nucleos(t)ide analogs therapy of hepatitis B?
    Chien RN
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1699-701. PubMed ID: 22097937
    [No Abstract]   [Full Text] [Related]  

  • 19. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
    Oh H; Yoon EL; Jun DW; Ahn SB; Lee HY; Jeong JY; Kim HS; Jeong SW; Kim SE; Shim JJ; Sohn JH; Cho YK;
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2793-2802.e6. PubMed ID: 32135246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.